URGN UroGen Pharma Ltd.

+0.09  (+0%)
Previous Close 36.56
Open 36.57
Price To Book 8.33
Market Cap 750461636
Shares 20,476,443
Volume 96,400
Short Ratio
Av. Daily Volume 130,920

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2019.
RTGel in combination with BOTOX
Overactive Bladder (OAB)
Phase 2a planned for 1H 2019.
Carcinoma In-Situ (CIS)
Phase 2b initial data due 2019.
VesiGel UGN-102
Low grade non-muscle invasive bladder cancer (LG-NMIBC)
Phase 3 data released January 8, 2019 noted 57% CR. Initiation of rolling NDA announced December 17, 2018. Presentation of data May 5, 2019 at AUA.
MitoGel - UGN-101
Urothelial Carcinoma

Latest News

  1. 3 International Companies Making Waves in the U.S. Soon
  2. 1 Under-the-Radar Healthcare Stock Wall Street Is Overlooking
  3. UroGen Pharma Announces Presentation of Analysis from Phase 3 OLYMPUS Trial of UGN-101 for Patients with Low-Grade Upper Tract Urothelial Cancer
  4. What Type Of Shareholder Owns UroGen Pharma Ltd.’s (NASDAQ:URGN)?
  5. UroGen Pharma to Present at March 2019 Investor Conferences
  6. UroGen Pharma Ltd. (URGN) Q4 2018 Earnings Conference Call Transcript
  7. UroGen Pharma to Report Fourth Quarter and Full Year 2018 Financial Results
  8. UroGen Pharma to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, February 28, 2019
  9. Factors of Influence in 2019, Key Indicators and Opportunity within Toyota Motor, UROGEN PHARMA, Macerich, Cosan, Middlesex Water, and Howard Hughes — New Research Emphasizes Economic Growth
  10. What Investors Should Know About UroGen Pharma Ltd.’s (NASDAQ:URGN) Financial Strength
  11. Don't Waste Your Money on Penny Stocks. These 3 Stocks Are Better Buys
  12. UroGen Pharma Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares
  13. Here's Why Urogen Pharma Fell as Much as 12.4% Today
  14. The Daily Biotech Pulse: Partial Clinical Hold On Advaxis Cervical Cancer Drug, Ohr's Reverse Split, Ironwood Starts Phase 1 Trial
  15. UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares
  16. The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoarthritis Drug Study
  17. UroGen Pharma Announces Proposed Public Offering of Ordinary Shares
  18. UroGen Pharma Announces Positive Results of UGN-101 from Pivotal Phase 3 OLYMPUS Trial for the Non-Surgical Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC)
  19. UroGen Pharma Appoints Elizabeth (Liz) Barrett as President and Chief Executive Officer
  20. Is UroGen Pharma Ltd. (URGN) A Good Stock To Buy?